Lynch & Associates IN Acquires 971 Shares of Eli Lilly and Company $LLY

Key Points

• Lynch & Associates IN increased its holdings in Eli Lilly and Company by 12.8% during the second quarter, acquiring an additional 971 shares, bringing its total to 8,564 shares valued at approximately $6.68 million.
• Eli Lilly reported a quarterly earnings per share of $6.31, exceeding analysts' expectations by $0.72, along with a 37.6% year-over-year revenue increase to $15.56 billion.
• Insider transactions included CEO David A. Ricks purchasing 1,632 shares at an average cost of $644.77, resulting in an increased ownership stake worth approximately $352 million.

Lynch & Associates IN raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 12.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,564 shares of the company's stock after acquiring an additional 971 shares during the quarter. Eli Lilly and Company comprises 1.3% of Lynch & Associates IN's portfolio, making the stock its 24th largest position. Lynch & Associates IN's holdings in Eli Lilly and Company were worth $6,676,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. PNC Financial Services Group Inc. boosted its stake in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock worth $10,495,261,000 after purchasing an additional 81,587 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Eli Lilly and Company by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock worth $4,808,443,000 after purchasing an additional 682,203 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 1.0%

Shares of NYSE:LLY opened at $747.29 on Wednesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.30. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company's fifty day simple moving average is $736.98 and its 200 day simple moving average is $768.86. The firm has a market cap of $707.27 billion, a price-to-earnings ratio of 48.84, a PEG ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the business posted $3.92 earnings per share. The firm's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 16th. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, Guggenheim reduced their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.